These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37732158)

  • 1. Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature.
    Kizilocak H; Guerrera MF; Young G
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102194. PubMed ID: 37732158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation.
    Harkins Druzgal C; Kizilocak H; Brown J; Sennett M; Young G
    J Thromb Haemost; 2020 Sep; 18(9):2205-2208. PubMed ID: 32544268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
    Kaneda M; Kawasaki R; Matsumoto N; Abe H; Tashiro Y; Inokuchi Y; Yasuno H; Sasaki-Noguchi M; Soeda T; Yoshimura Y; Oka T
    J Thromb Haemost; 2021 Dec; 19(12):2938-2946. PubMed ID: 34418287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation.
    Pezeshkpoor B; Sereda N; Becker-Gotot J; Berkemeier AC; Matuschek I; Müller J; Ramaraje Urs SU; Singh S; Klein C; Marquardt N; Oldenburg J
    J Thromb Haemost; 2024 Oct; ():. PubMed ID: 39401737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
    Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
    Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
    Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
    BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
    Nardi MA
    Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 11. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
    Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
    Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor.
    Valsecchi C; Gobbi M; Beeg M; Adams T; Castaman G; Schiavone L; Huntington JA; Peyvandi F
    J Thromb Haemost; 2021 Mar; 19(3):711-718. PubMed ID: 33370499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab.
    Novembrino C; Boscolo-Anzoletti M; Galbiati E; Shinohara S; Peyvandi F
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102260. PubMed ID: 38193066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 15. Emicizumab for the treatment of acquired hemophilia A.
    Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
    Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of Current and New Therapies for Hemophilia A.
    Prezotti ANL; Frade-Guanaes JO; Yamaguti-Hayakawa GG; Ozelo MC
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 35893734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
    Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
    J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.